Novagen Research Fund
North Bethesda, MD
- UEI
- FJ3XVN8S34N5
- CAGE
- 13NA0
- Primary NAICS
- 813212 Voluntary Health Organizations
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Tax Exempt)
- NAICS codes registered in SAM.gov
-
- 813212 Voluntary Health Organizations Primary
- 325414 Biological Product (except Diagnostic) Manufacturing
- 541690 Other Scientific and Technical Consulting Services
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration date
- Physical address
- 6116 Executive Blvd #444, North Bethesda, MD 20852, USA
- Website
- ngrf.org
- Industry
-
- Industrials
- Commercial & Professional Services
- Professional Services
- Research & Consulting Services
- SIC code
- 99 Non-Classifiable Establishments
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Shrna to a human endogenous retrovirus as a therapeutic approach to ALS | Defense Health Agency | $1,850,000 |
Quick answers
What is Novagen Research Fund's UEI?
Novagen Research Fund's Unique Entity ID (UEI) in SAM.gov is FJ3XVN8S34N5.
What is Novagen Research Fund's CAGE code?
Novagen Research Fund's CAGE code is 13NA0.
What is Novagen Research Fund's primary NAICS code?
Novagen Research Fund's primary NAICS code is 813212 (Voluntary Health Organizations).
Where is Novagen Research Fund located?
Novagen Research Fund's physical address in SAM.gov is 6116 Executive Blvd #444, North Bethesda, MD 20852, USA.
Is Novagen Research Fund registered in SAM.gov?
Yes. Novagen Research Fund's SAM.gov registration is active through May 29, 2027.
What is Novagen Research Fund's most recent federal award?
Novagen Research Fund's most recent federal grant award is Shrna to a human endogenous retrovirus as a therapeutic approach to ALS (HT9425261E345), from Defense Health Agency, on September 1, 2026.
On GovTribe
See Novagen Research Fund's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors